Evidence map›Paper›PMID 41166783›Full record

ArticlePediatric neurology2026

Risk of Seizures and Epilepsy in the Leukodystrophies.

Ashley N Hackett, Helena Yan, Katie Liu, Camille Corre, Kerry Gao, Chloe Grzyb, Jordan Goodman, Daniel Kelly, Cassandra R Ingemansson, Gabrielle Ghabash and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Pediatric neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ashley N HackettDivision of Pediatric Neurology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Texas Scottish Rite Hospital for Children, Dallas, Texas.
Helena YanLeukodystrophy Center, Department of Pediatrics, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York.
Katie LiuDivision of Pediatric Neurology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Camille CorreDepartment of Neurology, University of Rochester Medical Center, Rochester, New York.
Kerry GaoLeukodystrophy Center, Department of Pediatrics, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York.
Chloe GrzybDivision of Pediatric Neurology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jordan GoodmanThe Moser Center for Leukodystrophies, Kennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Daniel KellyDepartment of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Cassandra R IngemanssonDivision of Pediatric Neurology, University of California, Davis, Sacramento, California.
Gabrielle GhabashDivision of Pediatric Neurology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah.
Kerry DiBenardoDivision of Pediatric Neurology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Gerald V RaymondThe Moser Center for Leukodystrophies, Kennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
William BenkoDivision of Pediatric Neurology, University of California, Davis, Sacramento, California.
Robert Thompson-StoneDepartment of Neurology, University of Rochester Medical Center, Rochester, New York.
Ali FatemiThe Moser Center for Leukodystrophies, Kennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Florian S EichlerDepartment of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Stephanie KellerDivision of Pediatric Neurology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Joshua L BonkowskyDivision of Pediatric Neurology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah; Center for Personalized Medicine, Primary Children's Hospital, Salt Lake City, Utah.
Maria EscolarDivision of Pediatric Neurology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Eric J MallackLeukodystrophy Center, Department of Pediatrics, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York; The Moser Center for Leukodystrophies, Kennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: Mallack@kennedykrieger.org.

Funding

Validation of the GMFC-MLDU54NS115052 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI Laura Ann Adang, FLORIAN S EICHLER · 2019 to 2026
$14.3M
NINDS NIH HHS U54 NS115052
6 · The paper itself

Abstract

backgroundSeizures and epilepsy in leukodystrophies are poorly understood. This multisite study aimed to capture the prevalence of seizures in a nationwide cohort of patients, identify factors associated with increased seizure and epilepsy risk, and quantify prevalence of refractory seizures.

methodsRetrospective data was extracted from leukodystrophy clinics across eight pediatric health centers from January 1, 2013, to March 31, 2020. Patients 18 years old and younger and diagnosed with leukodystrophy, including those identified by newborn screening, were eligible. Epilepsy was defined as two or more unprovoked seizures. Clinical variables including patient age, diagnosis, imaging features (binary: normal vs abnormal), electroencephalogram (EEG) findings, the presence/absence, and diagnoses of seizures/epilepsy were obtained.

resultsData from 704 patients were analyzed. At least one seizure occurred in 29% of all patients. Epilepsy developed in 80% of patients with at least one seizure. EEG abnormalities were present in 84% of patients with seizures versus 54% without (P < 0.001). In a multivariate analysis of seizure risk, higher increased likelihoods were associated with every one-year increase in age (1.13 times higher; 95% confidence interval [CI]: [1.07, 1.19], P < 0.001), generalized epileptiform discharges (13.4 times higher; 95% CI: [2.22, 259], P = 0.019), focal and multifocal epileptiform discharges (3.56 times higher; 95% CI: [2.04, 6.36], P < 0.001), and focal slowing (3.57 times higher; 95% CI: [1.58, 8.58], P = 0.003). Diffuse slowing was not significantly associated with seizure in the multivariate analysis (odds ratio 1.45, 95% CI: [0.85, 2.45], P = 0.170). In a comparison of different pathological classifications, seizures, but not epilepsy, were more common in astrocytopathies compared to myelinopathies (seizures 41% vs 28%, P = 0.046; epilepsy 89% vs 79%, P = 0.376). Two or more antiseizure medications were required to control seizures in multiple leukodystrophies.

conclusionsAge, focal slowing, and epileptiform discharges, but not generalized slowing or abnormal brain magnetic resonance imaging, were significant predictors for seizure in this population. Patients with generalized discharges have a higher risk of seizures compared to those with focal discharges. Seizure burden, age at first seizure, number of antiseizure medications needed, and presence of EEG abnormalities vary based on underlying leukodystrophy. Our findings suggest the need for targeted strategies for monitoring seizures and epilepsy in the leukodystrophies.

Indexed as

EpilepsySeizuresAdolescentChildChild, PreschoolElectroencephalographyFemaleHumansInfantInfant, NewbornMalePrevalenceRetrospective StudiesRisk FactorsAntiseizure medicationElectroencephalogramEpilepsyLeukodystrophySeizures

Identifiers

PMID41166783
PMCPMC13670082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.